DKK428.00
4.46% today
Copenhagen, Apr 02, 05:00 pm CET
ISIN
DK0062266474
Symbol
GUBRA
Sector
Industry

Gubra A/S Stock price

DKK428.00
-222.00 34.15% 1M
-42.00 8.94% 6M
-196.00 31.41% YTD
+118.00 38.06% 1Y
+318.00 289.09% 3Y
+318.00 289.09% 5Y
+318.00 289.09% 10Y
Copenhagen, Closing price Wed, Apr 02 2025
-20.00 4.46%
ISIN
DK0062266474
Symbol
GUBRA
Sector
Industry

Key metrics

Market capitalization DKK7.31b
Enterprise Value DKK6.98b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 26.27
P/S ratio (TTM) P/S ratio 27.49
P/B ratio (TTM) P/B ratio 16.21
Revenue growth (TTM) Revenue growth 29.63%
Revenue (TTM) Revenue DKK265.74m
EBIT (operating result TTM) EBIT DKK-42.41m
Free Cash Flow (TTM) Free Cash Flow DKK-20.67m
EPS (TTM) EPS DKK-2.24
P/E forward 722.58
P/S forward 21.66
EV/Sales forward 20.69
Show more

Is Gubra A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Gubra A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Gubra A/S forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Gubra A/S forecast:

Buy
100%

Financial data from Gubra A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
266 266
30% 30%
100%
- Direct Costs 101 101
12% 12%
38%
165 165
43% 43%
62%
- Selling and Administrative Expenses 78 78
33% 33%
29%
- Research and Development Expense 113 113
27% 27%
43%
-27 -27
20% 20%
-10%
- Depreciation and Amortization 16 16
97% 97%
6%
EBIT (Operating Income) EBIT -42 -42
3% 3%
-16%
Net Profit -37 -37
18% 18%
-14%

In millions DKK.

Don't miss a Thing! We will send you all news about Gubra A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Gubra ApS operates as biotechnology company. It engages in the business of pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. The company operates through two business segments: CRO Services and Discovery & Partnerships. The CRO Services segment provides specialized pre-clinical contract research and development services for the pharmaceutical and biotechnology industry. The Discovery & Partnerships segment involves in discovery, design and development of peptide-based drug candidates with the aim of entering partnerships with pharmaceutical or biotechnology companies. Gubra was founded by Jacob Jelsing and Niels Vrang in 2008 and is headquartered in Horsholm, Denmark.

Head office Denmark
CEO Henrik Blou
Employees 260
Founded 2008
Website www.gubra.dk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today